<DOC>
	<DOCNO>NCT01764477</DOCNO>
	<brief_summary>Laboratory study suggest study drug may stop cancer cell grow affect interaction protein cell refer cAMP-response element-binding protein ß-catenin . The purpose research study determine high safe dose study drug may use give together chemotherapy drug patient cancer pancreas .</brief_summary>
	<brief_title>Safety Efficacy Study PRI-724 Plus Gemcitabine Subjects With Advanced Metastatic Pancreatic Adenocarcinoma</brief_title>
	<detailed_description>PRI-724 small molecule antagonist bind co-activator CBP thereby specifically inhibit subset Wnt/β-catenin-driven gene up-regulated cancer cell . PRI-724 develop potential antineoplastic agent . Purpose : To determine safety , tolerability , dose-limiting toxicity ( DLTs ) , maximum tolerate dose ( MTD ) sequential escalate dos per cohort PRI-724 administer combination gemcitabine patient adenocarcinoma pancreas locally advance , metastatic , otherwise inoperable , candidate second-line therapy fail first-line therapy FOLFIRINOX ( i.e. , folinic acid [ leucovorin ] , fluorouracil , irinotecan , oxaliplatin ) - PRI-724 : 320 , 640 , 905 mg/m2/day , continuous intravenous ( CIV ) infusion 24 h , daily × 7 day , 1 week 1 week recovery × 2 ( 4 week equal 1 cycle ) - Gemcitabine : 1000 mg/m2 IV 30 minute ; 3 week 1 week recovery ( 4 week equal 1 cycle ) Patients document , measurable evaluable adenocarcinoma pancreas locally advance , metastatic , otherwise inoperable , candidate second-line therapy fail first-line therapy FOLFIRINOX , enter phase 1b , multicenter , open-label , non-randomized , dose-escalation per cohort study . The trial design evaluate safety , tolerability , DLT ( ) , MTD escalate dos PRI-724 , CBP/ β- catenin inhibitor , administer combination standard dose gemcitabine . Correlative study include characterization PK profile PRI-724 gemcitabine , evaluation utility potential PD marker PRI-724 activity , well preliminary assessment antineoplastic activity PRI-724 plus gemcitabine patient population .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1 . Male female patient , &gt; 18 year age . 2 . Patients document ( histologically cytologicallyproven ) epithelial cell/adenocarcinoma pancreas relapse , locally advanced , metastatic . 3 . Patients measurable evaluable disease accord response evaluation criterion solid tumor 4 . Patients eligible secondline therapy fail firstline therapy regimen FOLFIRINOX . 5 . Patients malignancy currently amenable surgical intervention , due either medical contraindication nonresectability tumor . 6 . Patients Karnofsky Performance Status 70 % 100 % ( equivalent , Eastern Cooperative Oncology Group [ ECOG ] performance status 0 1 ) ; Performance Status Evaluation ) , anticipated life expectancy ≥ 3 month . 7 . Patients , male female , either childbearing potential agree use medically effective method contraception study 3 month last dose study drug . 8 . Patients ability understand give write informed consent participation trial , include evaluation procedure specify protocol . 1 . Women pregnant lactating . Women childbearing potential ( WOCBP ) fertile men WOCBP partner , use adequate birth control . 2 . Patients islet cell tumor nonepithelial cell malignancy pancreas . 3 . Patients know CNS ( leptomeningeal ) metastases control prior surgery radiotherapy , patient symptoms suggest CNS involvement treatment require . 4 . Patients active second malignancy within last 2 year exception : Treated , nonmelanoma skin cancer Treated CIS breast cervix Controlled , superficial bladder carcinoma T1a b prostate carcinoma involve &lt; 5 % resect tissue PSA within normal limit ( WNL ) since resection 5 . Patients follow hematologic abnormality baseline : Hemoglobin &lt; 9.0 g/dL Absolute neutrophil count ( ANC ) &lt; 1,500 per mm3 Platelet count &lt; 100,000 per mm3 6 . Patients follow serum chemistry abnormality baseline : Total bilirubin &gt; 1.5× ULN institution , unless consider due Gilbert 's Syndrome AST ALT &gt; 3× ULN institution ( &gt; 5× ULN due hepatic involvement tumor ) Serum albumin &lt; 2.5 g/dL Serum creatinine &gt; 1.5× ULN ( calculate creatinine clearance &lt; 60 mL/min/1.73 m2 ) 7 . Patients significant cardiovascular disease condition , include : Congestive heart failure ( CHF ) currently require therapy Need antiarrhythmic therapy ventricular arrhythmia Severe conduction disturbance Angina pectoris require therapy Left ventricular ejection fraction ( LVEF ) &lt; 50 % MUGA echocardiogram QTcF interval &gt; 450 msec ( male ) &gt; 470 msec ( female ) Uncontrolled hypertension ( per Investigator 's discretion ) Class III IV cardiovascular disease accord New York Heart Association 's ( NYHA ) Functional Criteria . Myocardial infarction ( MI ) within 6 month prior first study drug administration 8 . Patients know osteopenia osteoporosis . 9 . Patients know suspected hypersensitivity either gemcitabine component PRI724 . 10 . Patients history human immunodeficiency virus ( HIV ) active infection hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) . 11 . Patients serious/active/uncontrolled infection , infection require parenteral antibiotic , unexplained fever &gt; 38ºC within 2 week prior first study drug administration . 12 . Patients inadequate recovery acute toxicity associate prior antineoplastic therapy 13 . Patients inadequate recovery prior surgical procedure , patient undergo major surgical procedure within 1 month prior first study drug administration . 14 . Patients lifethreatening illness , significant organ system dysfunction , clinically significant laboratory abnormality , , opinion Investigator , would either compromise patient 's safety interfere evaluation safety study drug 15 . Patients psychiatric disorder alter mental status would preclude understand informed consent process and/or completion necessary study 16 . Patients inability , opinion Investigator , comply protocol requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>